'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News

5/16/24 11:03:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PDSB alert in real time by email

https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/

This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello, friends! I'm in San Francisco for the STAT Breakthrough Summit. Later today, I'll be "fireside chatting" with Cytokinetics CEO Robert Blum. It's not too late to join us virtually. Check out details here.

It's a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I'd call a biotech cult stock.

STAT+ EXCLUSIVE STORY

Already have an account? Log in

Get the next $PDSB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PDSB

Date	Price Target	Rating	Analyst
11/1/2022	$10.00	Buy	B. Riley Securities
8/12/2021	$20.00 → $15.00	Buy	HC Wainwright & Co.
6/28/2021	$25.00	Overweight	Cantor Fitzgerald

More analyst ratings

$PDSB
Financials

Live finance-specific insights

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administration ("FDA") regarding next steps in its planned Phase 3 clinical trial of its Versamune® based investigational immunotherapy designed to stimulate a targeted T cell attack against HPV
8/1/24 7:45:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET. Conference Call DetailsDate: August 1, 2024Time: 8:00 a.m. ET Dial-in: 1-877-704-4453 or 1-201-389-0920 Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prior to call) About PDS BiotechnologyPDS Biotechnology is a late-stage
7/31/24 4:01:00 PM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomized trial of triple combination in recurrent metastatic
3/27/24 7:30:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024. "We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team," said Frank Bedu-Addo, PhD, Pre
5/2/24 8:00:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or "the Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024. Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role. Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard. "We are please
1/22/24 4:45:19 PM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
11/28/23 8:30:00 AM ET
$APYX
$PDSB
$SSKN
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations

$PDSB
Press Releases

Fastest customizable press release news feed in the world

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
PRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the third quarter of 2024. "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive
11/14/24 8:00:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2024) in Seoul, South Korea. Details of the presentation are as follows: Date: Wednesday, October 23, 2024Session time: 08:30-10:10 Korean Stan
10/22/24 8:00:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88% (15/17) of patients had a complete metabolic responseIMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune® HPV (for
10/2/24 8:00:00 AM ET
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care

'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News

Chat with this insight

Recent Analyst Ratings for $PDSB

$PDSB Financials

Live finance-specific insights

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

$PDSB SEC Filings

SEC Form 10-Q filed by PDS Biotechnology Corporation

PDS Biotechnology Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

PDS Biotechnology Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$PDSB Leadership Updates

Live Leadership Updates

$PDSB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

B. Riley Securities initiated coverage on PDS Biotechnology with a new price target

HC Wainwright & Co. reiterated coverage on PDS Biotechnology with a new price target

Cantor Fitzgerald initiated coverage on PDS Biotechnology with a new price target

$PDSB Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $9

PDS Biotech Shares Data Update From Ongoing VERSATILE-002 Phase 2 Clinical Trial In Head and Neck Cancer

$PDSB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Freitag Gregory Gene

SEC Form 4 filed by Director Brawley Otis W

SEC Form 4 filed by Director Ali-Jackson Kamil

$PDSB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by PDS Biotechnology Corporation (Amendment)

SEC Form SC 13G filed by PDS Biotechnology Corporation

SEC Form SC 13G/A filed by PDS Biotechnology Corporation (Amendment)

$PDSB Press Releases

Fastest customizable press release news feed in the world

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Recent Analyst Ratings for
$PDSB

$PDSB
Financials

$PDSB
SEC Filings

$PDSB
Leadership Updates

$PDSB
Analyst Ratings

$PDSB
Market Insights

$PDSB
Insider Trading

$PDSB
Large Ownership Changes

$PDSB
Press Releases